Alkeon Capital Management LLC Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)

Alkeon Capital Management LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 18.7% during the 3rd quarter, Holdings Channel reports. The fund owned 1,897,601 shares of the company’s stock after buying an additional 298,694 shares during the quarter. Alkeon Capital Management LLC’s holdings in Keros Therapeutics were worth $110,194,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Keros Therapeutics by 4.7% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 50,552 shares of the company’s stock worth $2,936,000 after purchasing an additional 2,271 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Keros Therapeutics by 59.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock worth $312,000 after buying an additional 1,994 shares during the last quarter. FMR LLC raised its position in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock valued at $284,493,000 after buying an additional 179,374 shares during the period. Valence8 US LP acquired a new position in Keros Therapeutics in the third quarter valued at approximately $466,000. Finally, Charles Schwab Investment Management Inc. grew its position in Keros Therapeutics by 14.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Stock Performance

NASDAQ:KROS opened at $58.55 on Friday. Keros Therapeutics, Inc. has a 52 week low of $27.31 and a 52 week high of $73.00. The company has a fifty day simple moving average of $59.45 and a two-hundred day simple moving average of $52.27.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same period last year, the firm earned ($1.33) earnings per share. Keros Therapeutics’s quarterly revenue was up 4750.0% compared to the same quarter last year. Equities analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on KROS. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating on the stock. Scotiabank initiated coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Guggenheim started coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They set a “buy” rating and a $96.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.